Top

International Urology and Nephrology

Published in:

01-10-2017 | Nephrology - Original Paper

Smoking as a risk factor for diabetic nephropathy: a meta-analysis

Authors: Sensen Su, Wanning Wang, Tao Sun, Fuzhe Ma, Yue Wang, Jia Li, Zhonggao Xu

Published in: International Urology and Nephrology | Issue 10/2017

Abstract

Background

Previous studies have investigated the connection between diabetic nephropathy and smoking, and reported widely varying rates. This study aimed to systematically analyze the impact of smoking on diabetic nephropathy.

Methods

We searched the PubMed and EMBASE electronic databases to identify relevant English-language studies published up to March 2016. Eligible studies were selected using inclusion and exclusion criteria. Data for each study were extracted independently by two authors. The homogeneity of the effect size across the studies was tested. Odds ratio (OR) was calculated by using the random-effect model. Sensitivity analysis was performed to reduce heterogeneity, and publication biases were examined.

Results

A total of 21 eligible studies were selected and pooled analyzed. No significant differences in demographic characteristics were found between patients with diabetic nephropathy and those with non-diabetic nephropathy. Significant heterogeneity across studies was found except those of diabetes mellitus controls. The aggregate OR of smoking in the patients with diabetic nephropathy in comparison with those with non-diabetic nephropathy was 1.70 (95% confidence interval 1.48–1.95). No evidence of publication bias was found.

Conclusion

Our findings indicate that smoking is a significant risk factor for diabetic nephropathy in diabetic patients.

Duran-Salgado MB, Rubio-Guerra AF (2014) Diabetic nephropathy and inflammation. World J Diabetes 5(3):393–398CrossRefPubMedPubMedCentral

Sun Y-M, Su Y, Li J et al (2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 433(4):359–361CrossRefPubMed

Clair C, Cohen MJ, Eichler F et al (2015) The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med 30(8):1193–1203CrossRefPubMedPubMedCentral

Phisitkul K, Hegazy K, Chuahirun T et al (2008) Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci 335(4):284–291CrossRefPubMed

Byun S-H, Ma SH, Jun JK et al (2013) Screening for diabetic retinopathy and nephropathy in patients with diabetes: a nationwide survey in Korea. PLoS ONE 8(5):e62991. doi:10.1371/journal.pone.0062991 CrossRefPubMedPubMedCentral

Obert DM, Hua P, Pilkerton ME et al (2011) Environmental tobacco smoke furthers progression of diabetic nephropathy. Am J Med Sci 341(2):126–130CrossRefPubMedPubMedCentral

Hua P, Feng W, Ji S et al (2010) Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol-Renal Physiol 299(4):F732–F739CrossRefPubMedPubMedCentral

Tarnow L, Groop P-H, Hadjadj S et al (2008) European rational approach for the genetics of diabetic complications—EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 23(1):161–168. doi:10.1093/ndt/gfm501 CrossRefPubMed

Li H, Feng S-J, Zhang G-Z et al (2014) Correlation of lower concentrations of hydrogen sulfide with atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Blood Purif 38(3–4):188–194. doi:10.1159/000368883 CrossRefPubMed

10.

Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol: ASN. 2012070718

11.

Hovind P, Rossing P, Tarnow L et al (2003) Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 26(3):911–916CrossRefPubMed

12.

Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826CrossRefPubMed

13.

Feng RN, Zhao C, Sun CH et al (2011) Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS ONE 6(4):e18480. doi:10.1371/journal.pone.0018480 CrossRefPubMedPubMedCentral

14.

Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24(2):302–308. doi:10.1681/ASN.2012070718 CrossRefPubMedPubMedCentral

15.

Ahluwalia TS, Lindholm E, Groop L et al (2011) Uromodulin gene variant is associated with type 2 diabetic nephropathy. J Hypertens 29(9):1731–1734. doi:10.1097/HJH.0b013e328349de25 CrossRefPubMed

16.

Ahmed MA, Kishore G, Khader HA et al (2013) Risk factors and management of diabetic nephropathy. Saudi J Kidney Dis Transpl 24(24):1242–1247CrossRefPubMed

17.

Baum L, Ng MC, So WY, Lam VK et al (2005) Effect of hepatic lipase -514C- > T polymorphism and its interactions with apolipoprotein C3–482C- > T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in Chinese type 2 diabetic patients. Diabetes Care 28(7):1704–1709CrossRefPubMed

18.

Furukawa S, Yamamoto S, Todo Y et al (2014) Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetes mellitus. Endocr J 61(10):1011–1018CrossRefPubMed

19.

Hyvonen ME, Ihalmo P, Forsblom C et al (2012) INPPL1 is associated with the metabolic syndrome in men with type 1 diabetes, but not with diabetic nephropathy. Diabet Med 29(12):1589–1595. doi:10.1111/j.1464-5491.2012.03668.x CrossRefPubMed

20.

Khalid AR, Youssef AM, Subhani SN et al (2014) Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. PLoS ONE 9(2):e88956CrossRef

21.

Korpinen E, Groop PH, Rautio A et al (1999) N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy. Pharmacogenet Genomics 9(5):627–633CrossRef

22.

Lajer M, Jorsal A, Tarnow L et al (2010) Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 33(7):1567–1572. doi:10.2337/dc09-2174 CrossRefPubMedPubMedCentral

23.

Liu L, Zheng T, Wang F et al (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 33(1):144–149. doi:10.2337/dc09-1258 CrossRefPubMed

24.

Mollsten A, Marklund SL, Wessman M et al (2007) A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 56(1):265–269. doi:10.2337/db06-0698 CrossRefPubMed

25.

Ngarmukos C, Bunnag P, Kosachunhanun N et al (2006) Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. J Med Assoc Thai 89(Suppl 1):S37–S42PubMed

26.

Ozaki R, Cheung KKT, Wu E et al (2011) A new tool to detect kidney disease in Chinese type 2 diabetes patients: comparison of EZSCAN with standard screening methods. Diabetes Technol Ther 13(9):937–943. doi:10.1089/dia.2011.0023 CrossRefPubMed

27.

Rossing P, Hougaard P, Parving HH (2002) Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. BMJ 25(5):859–864

28.

Sawicki PT (1994) Smoking and diabetic nephropathy. Springer, USCrossRef

29.

Teratani G, Awano S, Soh I et al (2013) Oral health in patients on haemodialysis for diabetic nephropathy and chronic glomerulonephritis. Clin Oral Investig 17(2):483–489. doi:10.1007/s00784-012-0741-1 CrossRefPubMed

30.

Theilade S, Lajer M, Jorsal A et al (2012) Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with type 1 diabetes with and without diabetic nephropathy. Diabet Med 29(3):337–344. doi:10.1111/j.1464-5491.2011.03482.x CrossRefPubMed

31.

Zhang W, Yang Z, Li X et al (2015) The functional Q84R polymorphism of TRIB3 gene is associated with diabetic nephropathy in Chinese type 2 diabetic patients. Gene 555(2):357–361. doi:10.1016/j.gene.2014.11.031 CrossRefPubMed

32.

Zheng S, Powell DW, Zheng F et al (2016) Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis. J Diabetes Res 2016

33.

Kanwar YS, Wada J, Sun L et al (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 233(1):4–11CrossRef

34.

Ritz E, Ogata H, Orth S (2008) Smoking: a factor promoting onset and progression of diabetic nephropathy

35.

Voulgari C, Katsilambros N, Tentolouris N (2011) Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 60(10):1456–1464CrossRefPubMed

36.

Scott LJ, Warram JH, Hanna LS et al (2001) A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50(12):2842–2849CrossRefPubMed

37.

Prince CT, Secrest AM, Mackey RH et al (2010) Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes Care 33(3):652–657CrossRefPubMed

38.

Chakkarwar VA (2012) Smoking in diabetic nephropathy: sparks in the fuel tank? World J diabetes 3(12):186CrossRefPubMedPubMedCentral

Title: Smoking as a risk factor for diabetic nephropathy: a meta-analysis
Authors: Sensen Su
Wanning Wang
Tao Sun
Fuzhe Ma
Yue Wang
Jia Li
Zhonggao Xu
Publication date: 01-10-2017
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 10/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-017-1638-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2017

Evaluation of physical activity in sarcopenic conditions of kidney transplantation recipients

Position-related renal perfusion disturbances as a possible underestimated mechanism in patients with resistant hypertension: a case vignette

Expression of β-adrenergic receptor subtypes in human normal and dilated ureter

Klotho levels: association with insulin resistance and albumin-to-creatinine ratio in type 2 diabetic patients

Factors affecting responsiveness to hepatitis B immunization in dialysis patients

Novel porcine model for calcium oxalate stone formation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials